RFA-CA-19-031 Frequently Asked Questions

Cancer Prevention Clinical Trials Network (CP-CTNet): CP-CTNet Sites (UG1)- Re-Issuance

Last updated: August 15, 2019

Note: Questions have been modified for clarity and thus the answers in this FAQ document should be considered final.

1. (Received 7/1/19)  (For those applicants who submitted to CP-CTNet previously) Should we submit as amended application (i.e. introduction + showing changes in the application document)?  Or as a new application and address the critiques in the body of the application?

Answer: This will be considered a resubmission, so you should address the prior critique in the "Introduction to the Application" and make changes as applicable.  In the section about Additional Review Criteria (section V.1), Resubmissions, the standard verbiage says “For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project. “

2. (Received 7/1/19) Do we need to fill out the Human Subject Protection section since the proposed trials are samples for information only?

Answer: The Human Subject Protection Section should be filled out since CP-CTNet is a clinical program that will eventually fund multiple clinical trials.

3. (Received 8/15/19) Since we are required to complete the human subjects section for this grant, is it supposed to be general to incorporate all possible studies or is it to be specific to the sample concepts?

Answer: The Human Subject section should be general for the range of studies that you expect to perform. This means that it should cover the sample concepts as well. However, if there is something specific to the sample concepts that deserves mention, you may want to directly address it in the Human Subjects section as well.